Oncogenic mutations in the PI3K pathway are frequent in breast cancers and support cancer growth as well as resistance to HER2 targeting agents: PI3K or dual PI3K/mTOR inhibitors are able to kill breast cancer cells [18] and have demonstrated to have clinical benefits for the treatment of breast cancer carrying PI3K mutations [44]. This evidence concerns the gene ERBB2 and breast carcinoma.